Powder: -20°C for 3 years | In solvent: -80°C for 1 year
P7C3 是一种 aminopropyl carbazole 类化合物,具有口服活性,可透过血脑屏障,具有神经保护作用。它可用于神经退行性疾病,如帕金森病的研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 197 | 现货 | ||
5 mg | ¥ 455 | 现货 | ||
10 mg | ¥ 728 | 现货 | ||
25 mg | ¥ 1,370 | 现货 | ||
50 mg | ¥ 2,390 | 现货 | ||
100 mg | ¥ 3,990 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 490 | 现货 |
产品描述 | The P7C3 class of neuroprotective aminopropyl carbazoles has been shown to block neuronal cell death in models of neurodegeneration. We now show that P7C3 molecules additionally preserve axonal integrity after injury, before neuronal cell death occurs, in a rodent model of blast-mediated traumatic brain injury (TBI). This protective quality may be linked to the ability of P7C3 molecules to activate nicotinamide phosphoribosyltransferase, the rate-limiting enzyme in nicotinamide adenine dinucleotide salvage. |
体外活性 | In U2OS Cells, P7C3 protects cells from doxorubicin-mediated toxicity, and enhances the flux of nicotinamide through the NAMPT-mediated salvage pathway. [1] |
体内活性 | In mouse brain, P7C3 (40 mg/kg, p.o.) induces neurogenesis and enhances survival of newborn neurons. In npas3?/? mice, P7C3 (20 mg/kg/d, p.o.) increases the magnitude of neural precursor cell proliferation, and corrects morphological and electrophysiological deficits. [2] In the Ts65Dn mouse model of Down Syndrome, P7C3 restores hippocampal neurogenesis though a significant increase in total Ki67+, DCX+, and surviving BrdU+ cells. [3] |
激酶实验 | To assess the effect of compounds on auto-PARsylation of TNKS, 1 μM GST fusion protein containing the SAM domain and the PARP domain of TNKS2 (a.a. 872-1166) is mixed with 5 μM biotin-NAD+ and 2 μM XAV939 or LDW643 at 30°C for 2.5 hours. Samples are resolved by SDS-PAGE and probed with streptavidin AlexaFluor680. To assess PARsylation of axin, recombinant full-length TNKS2 (expressed/purified as a N-terminal His-tagged protein in bacteria) is incubated with GST-axin 1 (1-280) in the presence of biotin-NAD+ with or without XAV939. The products are resolved and probed with Streptavidin-HRP and imaged using a AlphaInnotech imager. To assess the effect of XAV939, IWR-1-enod, IWR-1-exo, and ABT-888 on auto-PARsylation of TNKS2, His-tagged full-length TNKS2 is incubated with 5 μM biotin-NAD+ and 3 mM of indicated compounds. The products are resolved and probed with Streptavidin-HRP. LC/MS-based high throughput auto-PARsylation assays for PARP1, PARP2, TNKS1, and TNKS2 are setup to monitor the formation of nicotinamide (a by-product of the PARsylation reaction) in the presence of small molecule inhibitors. |
分子量 | 474.19 |
分子式 | C21H18Br2N2O |
CAS No. | 301353-96-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 16 mg/mL (33.7 mM)
DMSO: 88 mg/mL (185.6 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.1089 mL | 10.5443 mL | 21.0886 mL | 52.7215 mL |
5 mM | 0.4218 mL | 2.1089 mL | 4.2177 mL | 10.5443 mL | |
10 mM | 0.2109 mL | 1.0544 mL | 2.1089 mL | 5.2721 mL | |
20 mM | 0.1054 mL | 0.5272 mL | 1.0544 mL | 2.6361 mL | |
DMSO | 50 mM | 0.0422 mL | 0.2109 mL | 0.4218 mL | 1.0544 mL |
100 mM | 0.0211 mL | 0.1054 mL | 0.2109 mL | 0.5272 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
P7C3 301353-96-8 Others inhibit injury Inhibitor nerve neurodegeneration neuroprotective Parkinson's neurodegenerative diseases disease cell P-7C3 inhibitor